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ttp://dx.doi.org/10.1016/j.ajpath.2012.11.038Prion diseases are neurodegenerative disorders characterized by the aberrant folding of endogenous
proteins into self-propagating pathogenic conformers. Prion disease can be initiated in animal models by
inoculation with amyloid ﬁbrils formed from bacterially derived recombinant prion protein. The synthetic
prions that accumulated in infected organisms are structurally distinct from the amyloid preparations
used to initiate their formation and change conformationally on repeated passage. To investigate the
nature of synthetic prion transformation, we infected mice with a conformationally diverse set of
amyloids and serially passaged the resulting prion strains. At each passage, we monitored changes in the
biochemical and biological properties of the adapting strain. The physicochemical properties of each
synthetic prion strain gradually changed on serial propagation until attaining a common adapted state
with shared physicochemical characteristics. These results indicate that synthetic prions can assume
multiple intermediate conformations before converging into one conformation optimized for in vivo
propagation. (Am J Pathol 2013, 182: 866e874; http://dx.doi.org/10.1016/j.ajpath.2012.11.038)Supported by NIH grants AG002132, AG10770, AG031220, and
AG021601 (S.B.P.), and by gifts from the G. Harold and Leila Y. Mathers
Charitable Foundation, Sherman Fairchild Foundation, Schott Foundation
for Public Education, and Rainwater Charitable Foundation.
Current address of S.G., Department of Biology, University of
Rochester, Rochester, New York; of D.W.C., Department of Chemical
Engineering, University of Delaware, Newark.In prion diseases, for example, Creutzfeldt-Jakob disease in
humans, scrapie in sheep, and bovine spongiform encepha-
lopathy in cattle, an aberrantly folded conformer of the prion
protein (PrP) propagates by catalyzing a posttranslational
conversion reaction, using cellular PrP (PrPC) as substrate.1,2
This conversion reaction transforms endogenous PrPC to the
pathogenic conformer PrPSc.3e5 Although self-replication of
protein conformations was previously thought to be a unique
feature of PrP prion diseases, in recent experiments, aggregates
of proteins that cause other neurodegenerative diseases, for
example, Ab,6e8 a-synuclein,9e11 tau,12,13 and huntingtin,14
stimulated the formation of pathogenic conformations in vivo.
Thus, it is likely that elucidating themechanisms of PrPSc prion
propagationwill provide important insights into the pathogenic
properties of a broad range of neurodegenerative disorders.
An important advance in prion biology was the creation
of infectious synthetic prion strains formed exclusively from
bacterially derived recombinant (rec) PrP.15e18 The ability
to create de novo synthetic strains has provided indisputable
evidence for the prion hypothesis and has facilitated struc-
tural studies with the objective of elucidating the structural
basis of protein-based infectivity. However, an enigmatic
feature of synthetic prion strains is that the conformationsstigative Pathology.
.that ultimately accumulate in infected organisms are struc-
turally distinct from recombinant amyloids used to initiate
their formation.19e21 In contrast, speciﬁc biochemical
features of the amyloid inocula, such as their conformational
stabilities, correlate with the prion strains induced in vivo.16
Thus, the mechanisms by which amyloid preparations are
transformed into transmissible prion strains in vivo remain
under investigation.22e24
In an earlier investigation into the transformation of prion
strains, we studied the mouse synthetic prion strain MoSP1,25
which was generated by inoculating transgenic (Tg) mice
expressing truncatedmousePrP(D23e88),whichwere denoted
as Tg9949 mice,26 with recPrP(D23e88) refolded into b-rich
amyloidﬁbrils.15After>500 days, the inoculated Tg9949mice
amassed protease-resistant infectious prions (rPrPSc).15 The
accumulated MoSP1 strain had two biochemical features that
Prion Strain Evolutiondifferentiated it from naturally occurring prion strains such
as the mouse-adapted Rocky Mountain Laboratory (RML;
Golden, CO) scrapie strain. First, MoSP1 PrPSc had a high-
conformational stability, requiring >4 mol/L guanidine
hydrochloride (GdnHCl) to unfold the prion aggregate and
render it susceptible to proteolysis.27 Second, the unglycosy-
lated protease-resistant core had a molecular weight of w19
kDa.25 By comparison, RML requiresw1.5 mol/L GdnHCl to
unfold and has a protease-resistant core of w21 kDa. We
showed that the difference inmolecularweights of the protease-
resistant cores of MoSP1 and RML was due to conformational
differences at their N-termini. When MoSP1 was continually
passaged inmice, its physicochemical properties transformed in
three ways: i) the unglycosylated protease-resistant core shifted
from a molecular weight ofw19 kDa tow21 kDa; ii) MoSP1
became conformationally less stable; and iii) the incubation
period of the strain decreased tow150 days. We were able to
recapitulate these transformations by propagating MoSP1 in
cell culture.25 We hypothesized that the mechanism of this
transformation involved rare conformational conversion events
followed by competitive selection among the resulting pool of
conformers.
After our previous study, it remained uncertain whether
the observed MoSP1 transition constituted a strain-speciﬁc
transformation or a common pathway for the in vivo adap-
tation of all mouse synthetic prion strains. To address this,
we created a conformationally diverse set of amyloids by
refolding recPrP under various denaturing conditions.16
These preparations were inoculated intracerebrally into Tg
mice overexpressing full-length PrP, denoted as Tg4053
mice.28 After the initially infected mice developed prion
disease, we serially passaged the resulting PrPSc strains
(MoSP5, MoSP6, MoSP7, and MoSP9) and monitored
changes in their biological and biochemical characteristics
including incubation period, rPrPSc banding patterns,
conformational stability, and ability to seed amyloid
formation in vitro. On initial infection, the synthetic prion
strains accumulated as a diverse set of conformations.
However, on repeated passage, all four synthetic prion
strains acquired the same set of physicochemical charac-
teristics including short incubation periods, low conforma-
tional stabilities, 21-kDa banding patterns for unglycosylated
rPrPSc, and diminished abilities to seed amyloid formation
in vitro. In addition, we tested the infectivity of MoSP7 in
three different cell lines and found an increased ability
to induce the cellular formation of rPrPSc on passage.Table 1 Conditions Used for Amyloid Preparation
Amyloid PrP sequence Urea concentration (mol/L)
MoSP5 23230 4
MoSP6 89230 4
MoSP7 89230 0.2
MoSP9 89230 0.5
The American Journal of Pathology - ajp.amjpathol.orgTogether, these results show that synthetic prions can
assume different intermediate conformations before
achieving a conformation that is optimized for in vivo
propagation.
Materials and Methods
Ethics Statement
All animal experiments were performed according to The
Guide for the Care and Use of Laboratory Animals
(National Research Council, 1996). All operations and
procedures were approved by the Institutional Animal Care
and Use Committee at the University of California San
Francisco.
Production of Amyloid Fibers
The expression and puriﬁcation of truncated recMoPrP
(89e230) and full-length recMoPrP(23e230) and the
formation of amyloid ﬁbers have been previously de-
scribed.15,29,30 In brief, lyophilized puriﬁed protein was dis-
solved in 10 mol/L urea at 10 mg/mL. Fibers were formed in
buffers (Table 1), with the addition of 30 mmol/L thioﬂavin
T (ThT). Protein concentrations ranged from0.2 to 1.0mg/mL.
Solution (200 mL per well) was added to 96-well plates and
continuously shaken at 37C in a plate reader. ThT ﬂuores-
cencewas detected at 442 nmexcitation and 485 nmemission.
Fibers were dialyzed against PBS to remove traces of urea and
other solution components before inoculation.
Mouse Bioassays
The creation and characterization of Tg4053 mice have been
previously described.31 The concentration of recMoPrP in the
inocula wasw0.5 mg/mL. Serial passage was conducted by
inoculation with brain homogenates in sterile PBS without
calcium or magnesium. Brain homogenates were prepared by
repeated extrusion through syringe needles of successively
smaller size, from 18 to 22 gauge. All work was performed in
laminar ﬂow hoods to prevent cross-contamination. Mice of
either sex, aged 7 to 10weeks, were inoculated intracerebrally
with 30 mL amyloid ﬁbrils or 1% brain homogenate for
passaging. Inoculation was performed using a 27-gauge
disposable hypodermic needle inserted into the right parie-
tal lobe. After inoculation, mice were examined daily forAcetate buffer
GdnHCl1/2 (mol/L)pH NaCl concentration (mol/L)
5 0.4 4.2
5 0.4 3.5
5 0.2 3.1
5 0.2 2.9
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used to identify animals exhibiting signs of prion disease.28,32
The indicated mice were sacriﬁced, and their brains were
removed for biochemical analysis.
Cell Culture
The N2a cell line was purchased from ATCC (Manassas,
VA). Cath.a-differentiated (CAD) and murine ﬁbroblast
cloned cell line L929 (LD9) were a gift from Charles
Weissmann. Cloning was performed by limiting dilution, as
previously described.33 Cells were infected via exposure to
the indicated brain homogenates, as previously described.33
N2a and CAD cells were maintained at 37C in 10 mL
Dulbecco’s modiﬁed Eagle’s medium supplemented with
10% fetal bovine serum (FBS), 1% penicillin-streptomycin,
and 1% L-glutamine (GlutaMAX; Invitrogen Corp., Carls-
bad, CA). LD9 cells were maintained in minimal essential
medium with 10% FBS, 1% penicillin-streptomycin, and
1% L-glutamine. Media were refreshed every 2 days. Cells
were propagated in 100-mm plates and allowed to grow to
95% conﬂuence before dissociation with 1 mL enzyme-free
cell-dissociation buffer. Cells were then replated at 10%
conﬂuence for further propagation. To collect cell lysates,
cells were rinsed three times with PBS (10 mL each) and
lysed with 1 mL cold lysis buffer [10 mmol/L Tris HCl (pH
8.0), 150 mmol/L NaCl, 0.5% Nonidet P-40, and 0.5%
sodium deoxychloate]. Lysates were centrifuged for 3
minutes at 10,000  g to remove cell debris, and the total
protein concentration was measured in the supernatant using
the bicinchoninic acid assay (Pierce Biotechnology, Inc.,
Rockford, IL). Aliquots containing 500 mg total protein
were titrated by adding lysis buffer to achieve a ﬁnal protein
concentration of 1 mg/mL and stored at 20C until further
analysis.
Western Blot Analysis, Conformational-Stability
Assays, and Densitometry
Nuclei and debris were removed from brain homogenates and
cell lysates via centrifugation at 1000  g for 10 minutes.
Cleared extracts were adjusted to 1 mg/mL protein in 100
mmol/L NaCl, 1 mmol/L EDTA, 2% sarkosyl, and 50mmol/L
Tris HCl (pH 7. 5). To achieve a protein/enzyme ratio of 50:1,
20 mg/mL proteinase K (PK; Boehringer Mannheim Corp.,
a division of Roche, Indianapolis, IN) was added to 0.5 mL
adjusted homogenate. This relative concentration of PK and
time of digestion have previously been shown to result in
complete digestion of PrPC and steady-state levels of protease-
resistant PrPSc.33 After incubation at 37C for 1 hour, proteo-
lytic digestion was terminated via addition of 8 mL 0.5 mol/L
phenylmethylsulfonyl ﬂuoride in absolute ethanol. Both
PK-digested and undigested samples were prepared for
12% SDSePAGE by mixing equal volumes of adjusted
homogenate and 2 sample buffer. After electrophoresis,
Western blot analysis was performed as previously described.868Membranes were blocked with 5% nonfat milk protein in
calcium- and magnesium-free PBS plus 0.1% Tween 20
(PBST) for 1 hour at room temperature. Blocked membranes
were incubated with primary PrP-speciﬁc recombinant Fab
human-mouse-D18 at 1 mg/mL in PBST for 1 hour at 4C.
After incubation with primary Fab, membranes were washed 3
times for 10 minutes in PBST, incubated with horseradish
peroxidaseelabeled anti-human Fab secondary antibody (ICN
Pharmaceuticals, Inc., Biomedical Division, Aurora, OH),
diluted 1:5000 in PBST for 25 minutes at room temperature,
and washed again 3 times for 10 minutes in PBST. After
chemiluminescent development using an ECL reagent
(Amersham Biosciences Corp., Piscataway, NJ) for 1 to
5 minutes, blots were sealed in plastic covers and exposed to
ECL Hypermax ﬁlm (Amersham).
The conformational-stability assay has been previously
described.34 In brief, 50 mL 10% brain homogenate or 1 mg/
mL cell lysate was mixed with 50 mL GdnHCl, varying from
0 to 6 mol/L, and incubated for 1 hour at room temperature.
For GdnHCl concentrations >4 mol/L, less volume of
extract was used. Before PK digestion, all samples were
diluted in lysis buffer to obtain GdnHCl concentrations of
0.4 mol/L. Densitometry on the appropriate bands was
performed using a CCD camera (FluorChem 8800; Alpha
Innotech Corp., San Leandro, CA). Measurements were
normalized with respect to the highest intensity band in the
denaturation curve. The half-maximal concentration of
GdnHCl (GdnHCl1/2) values were obtained by least-square
ﬁtting to the following sigmoidal equation: Y Z 1/[1 þ
(X/GdnHCl1/2)^ HC], where Y is the measured intensities, X is
the GdnHCl concentrations, and HC is the Hill coefﬁcient.
In Vitro Amyloid Assay
The amyloid formation assay was based on the real-time
quaking-induced conversion assay as described by Wilham
et al.35 Ten percent brain homogenates were obtained as
described (see Western Blot Analysis, Conformational-
Stability Assays, and Densitometry). To 90 mL brain
homogenate, 10 mL 10 clearance buffer [10% Triton X-100
(Sigma-Aldrich Corp., St. Louis, MO), 1.5 mol/L NaCl, and
40 mmol/L EDTA] was added, and the solution was centri-
fuged for 30 seconds at 1500 g on a tabletop centrifuge. The
supernatant was collected and frozen at 4C until further use.
The cleared homogenate was diluted in PBS containing 0.1%
SDS. The extent of dilution ranged from 50 to 300 based
on the intensity of the rPrPSc band on the Western blot.
RecMoPrP(89e230) to aﬁnal concentration of 20mg/mLwas
added to the reaction buffer, which consisted of 130 mmol/L
NaCl, 10 mmol/L sodium phosphate (pH 7.4), 10 mmol/L
EDTA, and 10 mmol/L ThT. The reaction buffer plus protein,
in 100-mL aliquots, were added to each well of a 96-well
microtiter plate, and 1 mL diluted brain homogenate was
added to each well. The plates were shaken at 42C for 48
hours, and readings were taken every 2 minutes at 442 nm
excitation and 485 nm emission. For each seed, six differentajp.amjpathol.org - The American Journal of Pathology
Prion Strain Evolutionwells were averaged to produce resulting traces plotted. The
“lag time” was calculated as the time by which the ﬂuores-
cence surpassed 3 SD of the initial baseline.
Neuropathologic Analysis
Brains were ﬁxed in 10% buffered formalin and embedded
in parafﬁn. Staining with H&E was performed on sections
8 mm thick. Peroxidase immunohistochemistry with anti-
bodies to glial ﬁbrillary acidic protein was used to evaluate
the degree of reactive astrocytic gliosis. Immunohisto-
chemistry of PrPSc was performed via the hydrated auto-
claving method using the PrP-speciﬁc human-mouse P and
R2 recombinant monoclonal antibody fragments (Fab).
Results
Characterization of Amyloid Fibrils and Serial Passage
in Mice
Creation of PrP amyloids used to generate the synthetic strains
analyzed in the present study (MoSP5, MoSP6, MoSP7, and
MoSP9) has been previously described.16 PrP amyloids were
created in buffers with varying pH, denaturant, and saltFigure 1 A: Kaplan-Meier survival curves of Tg4053 mice after inoculation with
second (P2, green), third (P3, blue), and fourth (P4, gray) passages. Three differ
(MoSP7a), and mixed type 1/2 (MoSP7c). Open circles indicate terminal mice t
biochemically analyzed and subsequently used as the inoculum for the next round
of the hippocampus (top panel) shows vacuolation. Immunohistochemistry with a
deposits. Staining with antibodies to GFAP (bottom panel) shows a mild level o
The American Journal of Pathology - ajp.amjpathol.orgconcentrations, and the polymerization reaction was per-
formed via continuous shaking at 37C (Table 1). The
resulting ﬁbrils had a range of conformational stabilities, as
determined by the concentration of GdnHCl required to
unmask antibody epitopes that are differentially exposed in
PrPSc and PrPC conformations (Table 1). The ﬁbril prepara-
tions also had varying morphologic features, as observed by
electron microscopy.16
The PrP preparations were inoculated intracerebrally into
Tg4053 mice overexpressing full-length mouse (Mo) PrP at
4 to 8 times the levels found in wild-type FVB mice.31
Mice infected with the amyloid preparations developed
neurologic disease at 450 to 800 days after inoculation16
(Figure 1A). The onset of disease was characterized by
the presence of vacuoles and astrocytic gliosis in the brain
(Figure 1B).16 Immunohistochemical analysis of infected
brains indicated the presence of rPrPSc 16 (Figure 1B).
Conversely, Tg4053 mice inoculated with PBS or bovine
serum albumin did not develop neurologic disease during
their lifespan and did not accumulate infectious prions in
their brain.17
Brain homogenates from infected mice were serially
passaged in Tg4053 mice for three or four rounds
(Figure 1A). For MoSP7, extracts from multiple initiallyMoSP5, MoSP6, MoSP7, and MoSP9. Colored curves indicate ﬁrst (P1, red),
ent MoSP7 isolates were passaged: predominantly type 1 (MoSP7b), type 2
hat were biochemically analyzed, and solid circles signify mice that were
of passage. B: Neuropathologic proﬁle for passage of MoSP7c. H&E staining
nti-PrP antibodies (middle panel) indicates the presence of granular PrPSc
f astrocytic gliosis. Scale bar Z 50 mm (all micrographs).
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Figure 2 Western blot analysis of selected Tg4053 mice (circles in
Figure 1) infected with synthetic mouse prions at different passages. Brain
homogenates were subjected to immunoblotting after limited digestion
with PK. Blots were probed with D18 antibody. RML and MoSP1 at passage
125 are shown as controls. Arrows denote the unglycosylated protease-
resistant bands of PrPSc migrating to 19 kDa (type 2) and 21 kDa (type
1). For passage of MoSP7c, two different mice are shown from second
passage, indicated as P2-1 and P2-2. Molecular masses of protein standards
are given in kilodaltons.
Ghaemmaghami et alinfected brains were used as inocula for additional rounds of
injection. On serial passaging, the incubation period for all
strains decreased stochastically. By the third or fourth
passage, the incubation periods of the synthetic prions
strains ranged from 80 to 300 days.
Neuropathologic analysis was consistent with prion
disease for all passages17 and indicated the presence of
punctate PrPSc deposits, varying degrees of vacuolation in
the neuropil, and different levels of reactive astrocyticFigure 3 Conformational stability of synthetic prion strains at different passage
PK-digested brain homogenate after incubation with increasing concentrations of Gdn
MoSP7 at second and third passages are shown. Blots were probed with D18 antibod
stabilities of all analyzed passaged synthetic mouse prion strains. GdnHCl1/2 values
870gliosis. No clear trends were evident between the degree of
these neuropathologic changes and passage number (data
not shown).
Biochemical Characterization
Brain extracts from selected infected mice (Figure 1A) were
digested with PK, and rPrPSc bands were detected on
Western blots using the D18 antibody36 (Figure 2). The
epitope of D18 lies between residues 132 and 157 of
MoPrP. Detected rPrPSc had variable banding patterns.
These patterns could be divided into three categories, with
the unglycosylated band having apparent molecular weights
of 21 kDa, 19 kDa, or a mixture of the two types; we refer to
these banding patterns as types 1, 2, and 1/2, respectively,
analogous to the nomenclature used for Creutzfeldt-Jakob
disease strains in humans.37 It is likely that each set of
bands represents a spectrum of protein conformations, given
the limited resolution of the Western blots. For comparison,
RML and ﬁrst-passage MoSP1,25 which have type 1 and
type 1/2 patterns, respectively, are shown in the immuno-
blot. On ﬁrst passage, MoSP5 and MoSP6 appeared as type
2 strains, MoSP9 appeared as type 1/2, and MoSP7 showed
all three strain types (Figure 2). By second passage, MoSP5,
MoSP6, and MoSP9 all transformed to a type 1 strain. On
second passage of MoSP7 type 2 (MoSP7a), a trans-
formation to type 1 occurred, similar to that observed for
MoSP5, MoSP6, and MoSP9. However, when predomi-
nantly type 1 (MoSP7b) and type 1/2 (MoSP7c) strains were
injected for a second passage, some mice showed type 2
PrPSc. After subsequent passages, a type 1 strain emerged
(fourth passage of MoSP7b and third passage of MoSP7c).s. A: As an example of a typical conformational stability assay, Western blot of
HCl (left panel) and the corresponding densitometry analysis (right panel) of
y. Molecular masses of protein standards are given in kDa. B: Conformational
were measured for each brain homogenate as shown in A.
ajp.amjpathol.org - The American Journal of Pathology
Figure 4 Graph showing changes in the incubation periods (abscissa),
banding patterns, and conformational stabilities (ordinate) of MoSP5,
MoSP6, MoSP7, and MoSP9 passaged in Tg4053 mice. Open, solid, and
half-solid circles represent type 1, 2, and 1/2 strains, respectively, for the
indicated synthetic prion inoculum and passage. Sold gray lines represent
the range of incubation periods observed for the bioassay from which the
analyzed mouse was selected.
Figure 5 In vitro amyloid seeding ability of passaged synthetic mouse
prions. A: Brain homogenates of Tg4053 mice after inoculation with
MoSP5, MoSP6, MoSP9, and MoSP7a, as indicated, at different passages
(indicated in different colors) were used to seed in vitro amyloid formation
using the real-time quaking-induced conversion assay. The concentration
of brain homogenate used as seed was normalized with respect to the total
PrPSc present in each extract. Homogenate from an uninfected brain (black
line) was used as a negative control. The kinetic traces show ThT ﬂuo-
rescence averaged for six wells in a microtiter plate and normalized with
respect to the ﬁnal signal. B: Lag time, or hours elapsed before ThT ﬂuo-
rescence attained 3 SD of the initial baseline, for each averaged kinetic
trace.
Prion Strain EvolutionThus, despite traversing different intermediate states, the
four strains ultimately converged on a type 1 banding
pattern.
We next measured the conformational stability of passaged
synthetic prion strains. The GdnHCl1/2 of PrP
Sc that accu-
mulated on initial passage ranged from 2.8 to 3.4 mol/L
(Figure 3). On continuous passage, the conformational
stabilities generally decreased for all mouse synthetic prions,
reaching w1.6 mol/L GdnHCl by third or fourth passage.
Quantitative changes in incubation periods, banding
patterns, and conformational stabilities of the mouse
synthetic prions on passage in Tg4053 mice are graphed in
Figure 4. For MoSP5, MoSP6, MoSP7a, and MoSP9
(Figure 4), the data indicate that serial passage results in i)
shortening of the incubation period, ii) a switch from type 2
or 1/2 to a type 1 banding pattern, and iii) a decrease in
conformational stability. These physicochemical changes
were also observed for MoSP1 in our earlier study. However,
forMoSP7 that emerged as predominantly type 1 and type 1/2
on ﬁrst passage, subsequent passages showed more complex
results. Some Tg4053 mice inoculated with MoSP7b or
MoSP7c for a second passage accumulated type 2 PrPSc with
relatively high conformational stability (GdnHCl1/2 >3.5
mol/L) and relatively short incubation periods (110 days).
We consider this combination of properties to be unusual
because in our previous studies, short incubation periods
correlated with low conformational stabilities and type 1
banding patterns.16,38 On subsequent passages, MoSP7b and
MoSP7c showed physicochemical characteristics similar to
the other mouse synthetic prions: incubation periods of
w100 days, type 1 PrPSc, and GdnHCl1/2 values of w1.6
mol/L. Together, these data argue that synthetic mouse prion
strains attain a similar set of physicochemical characteristics
on continuous propagation.The American Journal of Pathology - ajp.amjpathol.orgAmyloid Seeding Ability of Passaged Synthetic Mouse
Prion Strains
We next assessed the ability of passaged synthetic mouse
prion strains to seed the formation of amyloid ﬁbrils in vitro
using the real-time quaking-induced conversion assay.35 For
each synthetic strain, brain homogenates collected at each
passage were mixed with puriﬁed recPrP and incubated at
42C with continuous shaking. Fibril formation was quan-
tiﬁed by monitoring the change in ﬂuorescence intensity of
the dye ThT (Figure 5). The concentrations of brain
homogenates added to incubation buffers were normalized
on the basis of the intensities of rPrPSc bands on the Western
blots. All other buffer parameters were kept constant among
different kinetic experiments. For MoSP5, MoSP6, MoSP7,
and MoSP9, subsequent passage in Tg4053 mice decreased
the ability of the prions to seed amyloid formation, as
demonstrated by increased lag times for ThT kinetic traces.871
Figure 6 Infection of CAD, LD9, and N2a cells with MoSP7b at different
passages. Two different subclones of each cell line were incubated with
brain homogenates of Tg4053 mice infected with MoSP7b at different
passages. Western blots of PK-digested lysates indicate the presence of
protease-resistant PrPSc. For each indicated subclone, the two gel lanes
contain lysates taken after 8 and 9 weekly passages. Cells infected with RML
are shown as positive control. Blots were probed using D18. Molecular
masses of protein standards are given in kilodaltons.
Figure 7 Schema of a putative conformational landscape of a self-
propagating prion. Prions are capable of surveying a structural landscape
through rare stochastic conformational mutations. Initiating from an
amyloid ﬁbril with a relatively slow rate of in vivo propagation (A), prions
can traverse different intermediate states (B) and transform to a confor-
mation with a faster rate of replication (C).
Ghaemmaghami et alInfectivity of MoSP7 in Cultured Cells
We next assessed the ability of MoSP7, collected after
different passages, to infect a panel of three murine cell
lines: N2a, CAD, and LD9 (Figure 6). This panel of cell
lines had been previously used to differentiate a number of
prion strains.39 Each cell line was freshly cloned by limiting
dilution, and up to 10 clones were expanded for subsequent
analysis. For each cell line, we selected two clones that had
the highest level of PrPC expression, as determined by using
Western blot analysis (data not shown). These clones were
exposed to brain homogenates from P1, P2, and P4 of
MoSP7 lineage that was initiated by the accumulation of
a predominantly type 1 strain (MoSP7b). Cells were also
exposed to RML as a positive control. Infected cell lines
were passaged for eight rounds. Subsequently, cells were
lysed, and the resulting extract was analyzed for the pres-
ence of rPrPSc via Western blot analysis after limited PK
digestion. The results indicated that MoSP7 preparations
after P1 and P2 were able to infect LD9 cells only, whereas
MoSP7 after P4 was able to infect all three cell lines. Thus,
the host speciﬁcity of MoSP7 changed during the course of
its propagation in mice. The ability of MoSP7 to infect872a wider array of cell lines after P4 compared with the earlier
passages may be indicative of an increased level of
infectivity and/or a faster rate of replication attained during
serial passages in mice.
Discussion
In previous studies, prion disease could be induced in mice
by inoculation with amyloid preparations composed of
recPrP.15e18 The prion conformers that accumulated in the
brains of infected mice had some physicochemical proper-
ties that differed from the amyloid used for inoculation, as
evidenced by increases in resistance to proteolysis, changes
in seeding speciﬁcity, and structural transformations char-
acterized by X-ray diffraction19,20 as well as atomic force
and electron microscopy.21 Remarkably, amyloids created
under different in vitro conditions resulted in the accumu-
lation of conformationally distinct prion strains.16 In the
present study, for a diverse set of mouse synthetic prions,
we have shown that on continuous in vivo propagation, the
physiochemical properties of the strains changed until
a consensus state was reached. For the four synthetic mouse
prion strains analyzed, the strain changes that occurred on
repeated passage in vivo led to conformations that had
shorter incubation periods, lower conformational stabilities,
type 1 banding patterns, and decreased amyloid seeding
capability. For MoSP7, these changes also resulted in the
ability to infect a broader range of cell lines.
Our ﬁndings indicate that shorter incubation periods
in vivo do not correlate with amyloid seeding ability in vitro.
For a prion, the conformational properties that are optimal
for robust in vivo propagation are likely multifaceted. For
example, a robustly infectious prion strain must not only
propagate nascent PrPSc molecules but also be able to
survive cellular degradation processes and to horizontally
infect neighboring cells. It is likely that conformations
optimal for such in vivo requirements are not selectivelyajp.amjpathol.org - The American Journal of Pathology
Prion Strain Evolutionampliﬁed in in vitro amyloid ﬁbril formation assays. Thus,
when synthetic prion strains undergo in vivo changes, the
ability of the prion to propagate in vivo may be optimized at
the expense of its amyloid seeding kinetics. This observa-
tion is consistent with amyloid accumulation as a non-
obligatory feature of prion diseases.40
What is the molecular mechanism of in vivo synthetic prion
transformation? On the basis of our previous analysis of
MoSP1 in cell culture, we proposed that the transformation of
synthetic prions in vivo occurs through a process of competi-
tive selection.25 Prions typically have high replication speci-
ﬁcities and breed true on serial passage.41e43 However,
numerous studies have indicated that conformational changes
can occur in replicating prions.23,44e49Mechanistically, strain
transformations may occur either by rare spontaneous struc-
tural changes to the PrP aggregate or by infrequent lack of
ﬁdelity during the replication process.20,24 These low-
frequency conversion events result in formation of prion
conformations that structurally differ from their template. If
a mutated conformation is more proﬁcient at replicating in its
biological host, it is selectively ampliﬁed. In a heterogeneous
prion population, the presence of optimized strains will cause
the depletion of unoptimized strains by outcompeting them for
limited resources required for replication.As amixture, strains
are competing for the same pool of PrPC substrate and auxil-
iary factors required for de novo PrPSc formation. Thus, faster
replicating strains will deny slower strains of resources
required for their propagation. This process provides a mech-
anism by which an oligomeric conformer can stochastically
survey a conformational landscape and transform into
a structure that ismost proﬁcient at replicating in the biological
host (Figure 7). Thus, in this landscape view of prion trans-
formation, nonoptimized prion states can be initiated by awide
array of PrPSc structures and gradually transform into strains
with short incubation periods.
Our data not only show that a diverse set of synthetic prions
can gradually acquire the same set of physicochemical
properties on passage but also conﬁrm that parallel folding
pathways involving different intermediate states can be
traversed before reaching an optimized state. It is noteworthy
that some of the intermediate MoSP7 conformations charac-
terized in the present study have a combination of physico-
chemical properties not previously observed for natural prion
strains (type 2 banding patterns, high conformational
stability, and relatively short incubation periods), which
suggests that this conformation represents a metastable strain
that cannot propagate with ﬁdelity in vivo.
Not all prion strains are transient, and most natural strains
can propagate with a high degree of conformational ﬁdelity
over many rounds of passage. Why do not all strains
gradually transform to a single optimized state on perpetual
passage? As has been noted previously by Weissmann
et al,24 the conformational landscape of prions likely
encompasses a large number of local energy minima that
can indeﬁnitely trap structures not at the global energy
minimum. Thus, localization of the prion conformation onThe American Journal of Pathology - ajp.amjpathol.orgthe energy landscape, ie, whether a prion conformation is at
a local energy minimum, will determine whether the strain
is biologically stable or transient. The prion energy land-
scape is inﬂuenced by the sequence of PrP, and, thus, the
process of strain selection is expected to be host-dependent.
Future studies of heterologous synthetic prion propagation
in different transgenic mice might provide insight into the
relationship between the host PrP sequence and the prion
adaptation process.
Although it is now apparent that prions are dynamic
pathogens capable of altering their conformation to adapt to
new hosts and environments, the mechanistic details of this
evolutionary process remain under investigation.24 The
results of the present study demonstrate that diverse prions
can probe a structural landscape and traverse different
intermediate states to transform to an optimized conforma-
tion. That prions are capable of convergent evolution
suggests that an array of distinct conformers can initiate the
formation of a single biologically stable prion strain.References
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